Table 3.
Secondary outcome parameters
| Variable | Placebo (n = 8) | Eplerenone (n = 7) | p value |
|---|---|---|---|
| Δ Renin, µIU/ml | − 25.4 [− 216.9 to 15.5] | 14.5 [1.5–568.0] | 0.04 |
| Δ Aldosterone, pmol/l | − 14.5 [− 83.5 to 104.3] | 120.5 129.9 [120.5–215.9] | 0.05 |
| Δ eGFR, ml/min/1.73 m2 | − 0.7 ± 9.3 | − 2.1 ± 4.4 | 0.738 |
| Δ UPCR, mg/g | 86.50 ± 298.4 | − 346.1 ± 443.6 | 0.04 |
| Δ UACR, mg/g | 47.0 [11.0–80.3] | − 75.0 [− 486.0 to 324.0] | 0.52 |
| Δ RR systolic, mmHg | − 3.0 [− 12.8 to 22.8] | 0.0 [− 9.0 to 3.8] | 0.90 |
| Δ RR diastolic, mmHg | − 2.0 [− 6.8 to 5.0] | 5.5 [− 6.3 to 15.8] | 0.38 |
| Δ Potassium, mmol/l | − 0.06 [− 0.45 to 0.16] | 0.58 [0.31–0.90] | 0.00 |
| Δ PRA-S, pmol/l | 565.1 ± 921.9 | 746.7 ± 1058 | 0.02 |
| Δ ACE-S, (pmol/l)/(pmol/l) | 0.07 ± 0.20 | − 0.01 ± 0.03 | 0.23 |
Δ change from baseline, eGFR estimated glomerular filtration rate, UPCR urinary protein-to-creatinine ratio, UACR urinary albumin-to-creatinine ratio, RR blood pressure